Darbepoetin alfa (Aranesp™ Amgen), a novel erythropoietic agent with a longer serum half-life and greater in vivo biological activity than conventional recombinant human erythropoietin (HuEPO), has been shown to effectively alleviate anemia in patients with chronic anemia of cancer not receiving concomitant chemotherapy, according to results presented at the 38^th Annual Meeting of the American Society of Clinical Oncology, held in Orlando, Florida, from May 18 to 21, 2002.
Go to Previous Page
Go to Next Page